Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
*本文来源于近期《CEO杂志》对安斯泰来大中华商业总经理滨口洋先生的专访，全文如下：...
2022年9月21日，由安斯泰来资助的四年期公益项目——安徽糖尿病视网膜病变（简称“糖网”）防治模式试点项目在合肥正式启动。该项目经安徽省卫
结果显示，接受研究性enfortumab vedotin与pembrolizumab联合用药治疗的患者经证实的客观缓解率达64.5%...
Read more about 安斯泰来、Seagen和默克公布PADCEV®与可瑞达联合用药以及PADCEV单药在一线治疗晚期尿路上皮癌患者的临床试验研究结果
临床试验评价了30毫克剂量治疗绝经相关血管舒缩症（VMS）的安全性和耐受性...
Read more about 安斯泰来公布Fezolinetant在中国大陆的III期临床试验长期安全性研究的主要结果
2022年8月3日，由人民日报健康客户端、人民日报社健康时报主办的第十四届健康中国论坛年度榜单在北京揭晓，安斯泰来的富马酸吉瑞替尼片荣登2021
Follow China news
